IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study

References

• Bocouture^® Summary of Product CharacteristicsGermanyMerz Pharmaceuticals GmbH2014
   Google Scholar
• WenzelRJonesDBorregoJAComparing two botulinum toxin type A formulations using manufacturers’ product summariesJ Clin Pharm Ther200732438740217635341
   PubMed Web of Science ®Google Scholar
• CarruthersJFournierNKerscherMRuiz-AvilaJTrindade de AlmeidaARKaeuperGThe convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine – a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practiceDermatol Surg2013393 Pt 251052523458295
   PubMed Web of Science ®Google Scholar
• Vistabel^®. Summary of Product CharacteristicsIrvine, CA, USAAllergan, Inc2013
   Google Scholar
• AlimohammadiMAnderssonMPungaARCorrelation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized studyActa Derm Venereol201494323723975053
   PubMed Web of Science ®Google Scholar
• DresslerDBeneckeRPharmacology of therapeutic botulinum toxin preparationsDisabil Rehabil200729231761176818033601
   PubMed Web of Science ®Google Scholar
• CarruthersJDCarruthersJATreatment of glabellar frown lines with C. botulinum-A exotoxinJ Dermatol Surg Oncol199218117211740562
   PubMedGoogle Scholar
• FrevertJContent of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Drugs R D2010102677320698714
   PubMedGoogle Scholar
• GubanovaEIPanovaOSSanchezEARodinaMYStarovatovaPAEfficacy and safety of incobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot studyJ Drugs Dermatol201312121461146624301249
   PubMed Web of Science ®Google Scholar
• KaneMANonsurgical treatment of platysma bands with injection of botulinum toxin A revisitedPlast Reconstr Surg2003112Suppl 5125S126S14504493
   PubMedGoogle Scholar
• LeeJHParkJHLeeSKEfficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin AJ Dermatolog Treat201425432633023356833
   PubMed Web of Science ®Google Scholar
• Oliveira de MoraisOMatos Reis-FilhoEVilela PereiraLMartins GomesCAlvesGComparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot studyJ Drugs Dermatol201211221621922270205
   PubMed Web of Science ®Google Scholar
• PragerWDifferential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown linesClin Pharmacol20135395223516136
   PubMedGoogle Scholar
• CarruthersJALoweNJMenterMAA multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Am Acad Dermatol200246684084912063480
   PubMed Web of Science ®Google Scholar
• CarruthersJDLoweNJMenterMAGibsonJEadieNDouble-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar linesPlast Reconstr Surg200311241089109812973229
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJColemanWP3rdMulticenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesDermatol Surg201339455155823379292
   PubMed Web of Science ®Google Scholar
• HankeCWNarinsRSBrandtFA randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpointDermatol Surg201339689189923506308
   PubMed Web of Science ®Google Scholar
• SattlerGCallanderMGrablowitzDNoninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesDermatol Surg201036Suppl 42146215421134045
   PubMed Web of Science ®Google Scholar
• PragerWWissmüllerEKollhorstBWilliamsSZschockeIComparison of two botulinum toxin type A preparations for treating crow’s feet: a split-face, double-blind, proof-of-concept studyDermatol Surg201036Suppl 42155216021134046
   PubMed Web of Science ®Google Scholar
• MutiGEfficacy of incobotulinumtoxinA and onabotulinumtoxinA to treat crow’s feetSummer Academy Meeting of the American Academy of DermatologyAugust 6–10; 2014Chicago, IL
   Google Scholar
• LorencZPKenkelJMFagienSConsensus panel’s assessment and recommendations on the use of 3 botulinum toxin type A products in facial aestheticsAesthet Surg J201333Suppl 135S40S23515197
   PubMed Web of Science ®Google Scholar
• PoulainBTrevidicPClaveMClinical equivalence of conventional onabotulinumtoxinA (900 KDa) and incobotulinumtoxinA (neurotoxin free from complexing proteins – 150 KDa): 2012 multidisciplinary French consensus in aestheticsJ Drugs Dermatol201312121434144624301246
   PubMed Web of Science ®Google Scholar
• PragerWBeeEKHavermannIZschockeIOnset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical studyClin Interv Aging2013844945623650444
   PubMed Web of Science ®Google Scholar
• RapplTParviziDFriedlHOnset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind studyClin Cosmet Investig Dermatol20136211219
   Google Scholar
• AscherBTalaricoSCassutoDInternational consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) – part I: upper facial wrinklesJ Eur Acad Dermatol Venereol201024111278128420337830
   PubMed Web of Science ®Google Scholar
• PragerWHuber-VorlanderJTaufigAZBotulinum toxin type A treatment to the upper face: retrospective analysis of daily practiceClin Cosmet Investig Dermatol201255358
   Google Scholar
• AscherBZakineBKestemontPBaspeyrasMBougaraASantiniJA multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJ Am Acad Dermatol200451222323315280841
   PubMed Web of Science ®Google Scholar
• KaneMABrandtFRohrichRJNarinsRSMonheitGDHuberMBEvaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled studyPlast Reconstr Surg200912451619162919584772
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJA single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacyJ Am Acad Dermatol200960697297919467368
   PubMed Web of Science ®Google Scholar
• Azzalure^®. Summary of Product CharacteristicsHertfordshire, UKGalderma (UK) Ltd2010
   Google Scholar